WO2013051266A1 - タウ凝集阻害剤 - Google Patents
タウ凝集阻害剤 Download PDFInfo
- Publication number
- WO2013051266A1 WO2013051266A1 PCT/JP2012/006363 JP2012006363W WO2013051266A1 WO 2013051266 A1 WO2013051266 A1 WO 2013051266A1 JP 2012006363 W JP2012006363 W JP 2012006363W WO 2013051266 A1 WO2013051266 A1 WO 2013051266A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- tau
- isoprenaline
- tau aggregation
- shows
- aggregation inhibitor
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
- A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the present invention relates to a tau aggregation inhibitor that inhibits formation of tau aggregates that cause nerve loss and synapse loss.
- AD Alzheimer's disease
- Dementia is a type of dementia whose main symptoms are cognitive decline and personality changes.
- Dementia is a common disease that affects about 25% of the Japanese population over the age of 85, and AD accounts for about half of the population.
- AD accounts for about half of the population.
- acetylcholinesterase inhibitors currently being effective for the prevention and treatment of AD are only partially effective in mild to moderate patients, and a negative view of their effectiveness in patients with advanced disease There are many.
- AD neuropathological findings in AD patients are characterized by two features: senile plaques composed of ⁇ -amyloid and neurofibrillary tangles (NFT) formed by abnormal polymerization of tau protein
- NFT neurofibrillary tangles
- Tau protein is abundant in central neurons and is essential for the function of the nerve axons that make up the neural network of the brain. However, if tau protein forms insoluble aggregates in cells, axonal transport is successful. It causes the death of nerve cells.
- Patent Document 1 describes a drug mainly composed of a naphthoquinone type compound that inhibits tau aggregation for the improvement of AD symptoms. According to this drug, intracellular tau aggregation is suppressed to some extent, and thus, the symptoms of AD are alleviated by suppressing the formation of NFT.
- tau aggregation inhibitor does not have sufficient inhibition of intracellular tau aggregation, and it cannot be said that tauopathy including AD is treated accurately.
- the present invention has been made in view of such problems, and an object thereof is to provide a tau aggregation inhibitor capable of sufficiently suppressing intracellular tau aggregation.
- the tau aggregation inhibitor of the present invention is characterized by containing isoprenaline or a salt thereof.
- Isoprenaline can be in d-form.
- isoprenaline can be in d / l form.
- d-isomer or d-isoprenaline means (S)-(+)-isoprenaline, d / l-isomer or d / l-isoprenaline means (S)-(+)-isoprenaline, (R)- (-)-Isoprenaline mixture is shown.
- the tau aggregation inhibitor of the present invention comprises a catechol structure-containing compound or a salt thereof selected from the group consisting of dopamine, dobutamine, levodopa, levodopa / carbidopa, trimethquinol, hexoprenalin, methyldopa, and droxidopa. To do.
- intracellular tau aggregation can be sufficiently suppressed.
- AD tauopathy
- many societies have been improved by improving the lives of the elderly, reducing the burden of care, and reducing medical expenses. Contribution can be made.
- FIG. 2 is a graph showing thioflavin T activity, of which (a) is (R)-( ⁇ )-epinephrine, (b) is levodopa, (c) is dopamine, (d) is norepinephrine, (e) is thioflavin T of isoprenaline.
- the activity suppression effect is shown. It is a result of SDS (sodium dodecyl sulfate) -PAGE Western blotting showing the effect of inhibiting aggregation of tau detected by sucrose density gradient centrifugation, of which (a) is (R)-(-)-epinephrine, (b ) Shows the results for isoprenaline.
- FIG. 1 It is a figure which shows the increase in the amount of tau and acetylated tubulin in the microtubule fraction of isoprenaline, of which (a) is the tau of the microtubule fraction, (b) is the tau of the total fraction, (c) Is a graph of (a) showing that isoprenaline increases the amount of tau in the microtubule fraction. (D) acetylated tubulin in the microtubule fraction, (e) detected acetylated tubulin in the total fraction, (f) graphed (d), and isoprenaline in the microtubule fraction. It shows increasing the amount of acetylated tubulin.
- FIG. 1 shows the increase in the amount of tau and acetylated tubulin in the microtubule fraction of isoprenaline, of which (a) is the tau of the microtubule fraction, (b) is the tau of the total fraction, (c) Is a graph of
- FIG. 5 is a graph showing a decrease in sarkosyl-insoluble tau in the brain by isoprenaline in a mouse overexpressing human P301L mutant tau (P301L tau Tg mouse), of which (a) shows a detected sarkosyl-insoluble fraction, (b ) Is a graph of (a) showing that isoprenaline reduces the amount of sarkosyl-insoluble tau in the brain of P301L tau Tg mice.
- FIG. 1 It is a figure which shows that the isoprenaline suppresses the reduction
- FIG. 4 is a graph showing increased dephosphorylation of TBS soluble tau by isoprenaline in mice overexpressing wild-type tau (WT tau Tg mice), of which (a) shows the detection of dephosphorylation of TBS soluble fraction with tau1 antibody. (B) shows the ratio of dephosphorylated tau to tau. It is a figure which shows the change of the thioflavin T activity by d-isoprenaline, (a) is d-isoprenarin, (b) has shown the thioflavin T activity inhibitory effect of d / l-isoprenaline.
- (C) is a graph showing a measurement of the diameter of tau aggregates, which shows that d-isoprenalin reduces the number of granular tau aggregates and tau fibers.
- the cerebral cortex of P301L tau Tg mice it is a diagram showing the decrease of sarkosyl-insoluble tau by d-isoprenalin, of which (a) shows tau of sarkosyl-insoluble fraction, and (b) shows tau in TBS-soluble fraction.
- GAPDH intrasic control.
- the catechol structure-containing compound here is a compound containing a catechol structure in the structural formula.
- the catechol structure means a structure of catechol, which is a compound in which two of the substituents are hydroxyl groups, and the two hydroxyl groups are in a 1-position and 2-position relationship.
- the catechol structure-containing compound is specifically selected from the group consisting of isoprenaline, dopamine, dobutamine, levodopa, levodopa / carbidopa, trimethquinol, hexoprenalin, methyldopa and droxidopa.
- these catechol structure-containing compounds may be used singly or in combination.
- isoprenaline As isoprenaline, any of l-form (R configuration), d-form (S configuration), or d / l-form can be suitably used.
- the side effects of isoprenaline include increased heartbeat and myocardial ischemia, and isoprenaline has a stronger effect in the l form than in the d form, and the degree of the side effect is larger in the order of the l form, d / l form, and d form. .
- d-isoprenalin has almost the same tau aggregation inhibitory effect as d / l-isoprenalin. Therefore, among optical isomers, d-isomer is considered to be most preferable when isoprenaline is used as a therapeutic agent for dementia in the sense that it has almost the same tau aggregation inhibitory effect but has few side effects.
- the salts of these catechol structure-containing compounds are pharmacologically acceptable salts such as alkali metal salts (for example, potassium salts, sodium salts), alkaline earth metal salts (for example, magnesium salts, calcium salts, etc.), etc.
- alkali metal salts for example, potassium salts, sodium salts
- alkaline earth metal salts for example, magnesium salts, calcium salts, etc.
- alkali metal carbonates eg, lithium carbonate, potassium carbonate, sodium carbonate, cesium carbonate, etc.
- alkali metal hydrogen carbonates eg, lithium hydrogen carbonate, sodium bicarbonate, potassium hydrogen carbonate, etc.
- alkali metal hydroxides Salts of inorganic bases such as sodium hydroxide and potassium hydroxide; trialkylamines such as trimethylamine and triethylamine; pyridine, quinoline, piperidine, imidazole, picoline, dimethylaminopyridine, dimethylaniline, N- Alkyl-morpholine, DBN, DB Salts of organic bases such as: salts of inorganic acids such as hydrochloride, hydrobromide, hydroiodide, sulfate, nitrate, phosphate; formate, acetate, propionate, oxalate , Malonate, succinate, fumarate, maleate, lactate, malate, citrate, tartrate, citrate, carbonate, pic
- the tau aggregation inhibitor according to this embodiment can also contain at least one effective amount selected from the group consisting of a catechol structure-containing compound and a salt thereof together with a pharmaceutically acceptable carrier.
- a pharmaceutically acceptable carrier a solid such as an excipient or a liquid such as a diluent is used. Specific examples include magnesium stearate, lactose, starch, gelatin, agar, talc, pectin, gum arabic, olive oil, sesame oil, cocoa butter, ethylene glycol, distilled water and the like.
- Tauopathy is a neurodegenerative disease in which phosphorylated tau is accumulated in nerve cells and glial cells.
- Tauopathy is, for example, AD, Down's syndrome, Pick's disease, cortical basal ganglia degeneration (CBD), progressive supranuclear palsy (PSP) and the like.
- the tau aggregation inhibitor according to this embodiment is appropriately mixed with one or more additives selected from pharmaceutically acceptable isotonic agents, buffers, solubilizers, preservatives, and pH adjusters. Can do.
- the isotonic agent for example, potassium chloride, sodium chloride, boric acid, mannitol, glycerin, propylene glycol, polyethylene glycol, maltose, sucrose, sorbitol, glucose and the like can be used.
- buffer examples include organic acids such as amino acids and succinic acid, inorganic acids such as boric acid and phosphoric acid, and pharmaceutically acceptable salts thereof.
- solubilizing agents include polymers such as polyethylene glycol, polyvinyl pyrrolidone, polyvinyl alcohol, and hydroxypropyl methylcellulose; surfactants such as polysorbate, polyoxyethylene hydrogenated castor oil, and polyoxyethylene polyoxypropylene; propylene glycol and the like Polyhydric alcohols; organic acids such as benzoic acid and sorbic acid; amino acids such as aspartic acid, histidine, glycine and lysine can be used.
- preservative examples include quaternary ammonium salts such as benzethonium, benzalkonium, and benzododecinium, salts of cationic compounds such as chlorhexidine, and paraoxybenzoic acid esters such as methyl paraoxybenzoate and propyl paraoxybenzoate.
- quaternary ammonium salts such as benzethonium, benzalkonium, and benzododecinium
- salts of cationic compounds such as chlorhexidine
- paraoxybenzoic acid esters such as methyl paraoxybenzoate and propyl paraoxybenzoate.
- Alcohol compounds such as chlorobutanol and benzyl alcohol can be used.
- pH adjusters include sulfuric acid, hydrochloric acid, acetic acid, lactic acid, calcium hydroxide, potassium hydroxide, sodium hydroxide, magnesium hydroxide, monoethanolamine, triethanolamine, diisopropanolamine, triisopropanolamine, etc. can do.
- the dose of the tau aggregation inhibitor according to this embodiment is not particularly limited as long as an appropriate effect is produced, and is appropriately determined in consideration of the symptom level, sex, age, etc. of the patient to be administered.
- the amount of the tau aggregation inhibitor can be 0.0001 to 1000 mg per adult per day. This daily dose may be administered once a day, but is preferably divided into several times a day.
- the tau aggregation inhibitor according to this embodiment can be prepared in a dosage form according to the administration mode.
- the oral administration form include solid preparations such as granules, pills, tablets, capsules, powders, and liquids, and liquid forms.
- parenteral administration form it can be set as injection forms, such as an intravenous injection and an intramuscular injection, for example.
- tau When tau is phosphorylated, it associates to form a tau oligomer. When this tau oligomer grows and has a ⁇ -sheet structure, spherical granular tau aggregates are formed. Granular tau aggregates are thought to be composed of about 40 tau molecules. These granular tau aggregates are linked to form a tau fiber called a paired helical filament (PHF) (NFT).
- PHF paired helical filament
- the tau aggregation inhibitor according to the present embodiment not only inhibits tau aggregation in the process in which granular tau aggregates are linked to form PHF, but also tau aggregation in the process of forming spherical granular tau aggregates. It also inhibits. Moreover, degeneration of brain neurons occurs not only by mutant tau protein but also by accumulation of normal tau protein, but the tau aggregation inhibitor of the present invention also inhibits aggregation of normal tau protein. Therefore, it becomes possible to prevent or treat tauopathy symptoms including AD.
- Example 1 We searched for compounds that can bind to tau. 10 ⁇ M 2N4R tau (Tau-441 human) and 10 ⁇ M heparin were mixed and incubated at 37 ° C. to aggregate tau. This agglomerated tau sample (1 ml) was loaded into a sucrose density gradient solution (20 ml, 30%, 40%, 50% in 1 ml layers) and centrifuged (200000xg, 2 h, 20 ° C.). Thereafter, 1 ml each of the solution was collected from the upper layer to obtain a sample of fraction (Fr) 1-5. The pellet was suspended in HEPES solution to give Fr6. Thereafter, the binding ability between tau contained in Fr1, 3, and 5 and predetermined 6600 compounds was analyzed by the surface plasmon resonance method.
- the surface plasmon resonance method is a technique for analyzing the intermolecular interaction between two kinds of substances by monitoring a change in refractive index caused by a change in the weight of a molecule fixed on a thin gold film.
- the surface plasmon resonance method can be performed by a commercially available surface plasmon resonance apparatus, for example, BIAcore 2000 (manufactured by Pharmacia Biosensor). As a result, it was found that 111 compounds out of 6600 compounds bind to tau.
- Example 2 Next, whether or not (R)-( ⁇ )-epinephrine and pyrocatechol violet similar structures suppress tau aggregation was analyzed by thioflavin T staining.
- levodopa, dopamine, norepinephrine, and isoprenaline significantly reduced thioflavin T activity, similarly to (R)-( ⁇ )-epinephrine.
- 1 (a) is (R)-( ⁇ )-epinephrine
- FIG. 1 (b) is levodopa
- FIG. 1 (c) is dopamine
- FIG. 1 (d) is norepinephrine
- FIG. 1 (e) isisoprenaline. Shows changes in thioflavin T activity due to.
- FIG. 2 (a) shows the tau aggregation inhibitory effect of (R)-( ⁇ )-epinephrine
- FIG. 2 (b) shows the tau aggregation inhibitory effect of isoprenaline.
- isoprenaline is an existing drug and is considered to be safer than other catecholamine drugs. Therefore, below, it analyzed using isoprenaline.
- Example 3 Next, it was examined whether isoprenaline suppresses tau aggregation in cultured cells.
- the cells used were Neuro2a cell line in which human P301L mutant tau (tau in which the 301 th proline of the tau isoform was mutated to leucine) was expressed in a stable manner. These cells were treated with isoprenaline at concentrations of 0.01, 0.1 and 1 ⁇ M for 48 hours. Thereafter, SDS-insoluble fractions were collected and examined for changes in the amount of tau. As a result, as shown in FIG.
- isoprenaline is a positive control GSK3 ⁇ (glycogen synthase kinase 3 ⁇ ) inhibitor (meaning a substance that physically or chemically inhibits the function of GSK3 ⁇ ) and lithium chloride.
- GSK3 ⁇ glycose kinase 3 ⁇
- Fig. 3 (a) shows the detection of tau in the SDS-insoluble fraction
- Fig. 3 (b) is a graph of Fig. 3 (a)
- isoprenaline shows that the amount of SDS-insoluble tau is decreased. Show.
- FIG. 4 (a) shows the detection of phosphorylated tau (AT8 site) and tau in the RIPA soluble fraction
- FIG. 4 (b) shows the ratio of phosphorylated tau to tau.
- Example 4 It is known that tau phosphorylation of AT8 induces tau structural changes (detectable with MC1 antibody) observed in AD pathology. Therefore, WT tau was expressed in COS-7 cells (derived from African green monkey kidney), and tau structural change was detected by dot blot method using MC1 antibody. In the dot blot method, proteins are immobilized on a nitrocellulose membrane or PVDF membrane without being separated by electrophoresis, and the amount of protein is specifically quantified with an enzyme-labeled antibody. As a result, as shown in FIGS. 5 (a) and 5 (b), isoprenaline decreased the tau structural change detected with the MC1 antibody.
- FIG. 5 (a) and 5 (b) isoprenaline decreased the tau structural change detected with the MC1 antibody.
- FIG. 5 (a) shows MC1 antibody positive tau, tau phosphorylation (AT8 site), tau and GAPDH (endogenous control) detected in the TBS soluble fraction
- FIG. 5 (b) shows MC1 antibody against tau. The percentage of positive tau is indicated.
- isoprenaline also decreased phosphorylation under the same conditions.
- FIG. 5C shows the ratio of phosphorylated tau to tau.
- Example 5 We investigated how isoprenaline affects the binding of microtubules to tau.
- COS-7 cells expressing WT tau were treated with 10 ⁇ M of isoprenaline for 24 hours and then homogenized with RA buffer (0.1 ⁇ M MES, 0.5 mM MgSO 4 , 1 mM EGTA, 2 mM DTT, 0.1% TritonX-100, 20 ⁇ M taxol, 2 mM GTP) did. After centrifugation at 3000 ⁇ g for 5 minutes at 25 ° C., the supernatant was collected as a total fraction.
- RA buffer 0.1 ⁇ M MES, 0.5 mM MgSO 4 , 1 mM EGTA, 2 mM DTT, 0.1% TritonX-100, 20 ⁇ M taxol, 2 mM GTP
- microtubule fraction was collected from COS-7 cells expressing WT tau, and acetylated tubulin, which is an indicator of tau and microtubule stabilization, was detected.
- FIG. 6A shows the tau of the microtubule fraction
- FIG. 6B shows the tau of the total fraction
- FIG. 6C is a graph of FIG. 6A.
- FIG. 6 (d) is the acetylated tubulin of the microtubule fraction
- FIG. 6 (e) is the acetylated tubulin of the total fraction
- FIG. 6 (f) is a graph of FIG. 6 (d). It is.
- Example 6 it was examined whether isoprenaline suppresses tau aggregation in mice.
- P301L tau Tg mice were ingested for 3 months with isoprenaline (1.5 mg / g fed) mixed in powdered diet. Thereafter, cerebral cortex and hippocampus were collected from the mice and stored at ⁇ 80 ° C.
- cerebral cortex and hippocampus were collected from the mice and stored at ⁇ 80 ° C.
- a TBS solution was added to the frozen tissue, homogenized, and then centrifuged (23000 rpm, 15 min, 4 ° C.) to separate into a supernatant and a pellet. Among them, the supernatant was used as a TBS soluble fraction (including soluble tau).
- sucrose was added to the pellet, homogenized again, and then centrifuged (23000 rpm, 15 min, 4 ° C.) to separate into a supernatant (including tau aggregates) and a pellet (including nuclei). Thereafter, a surfactant (1% sarkosyl) was added to the supernatant, incubated (37 ° C., 1 h), and centrifuged (200000 ⁇ g, 1 h, 4 ° C.). The pellet was dissolved in a Remli buffer (containing 2-mercaptoethanol) to obtain a sarkosyl insoluble fraction. Tau in TBS soluble fraction and sarkosyl insoluble fraction was detected by SDS-PAGE Western blot.
- a surfactant 1% sarkosyl
- FIG. 7 shows the detection of tau in the sarkosyl-insoluble fraction
- FIG. 7B shows the quantitative and graphed result of FIG. 7A.
- Ntg means Non-transgenic mouse.
- Example 7 In the brain of P301L tau Tg mice, the number of neurons decreases as tau aggregation progresses. For this reason, isoprenaline having a tau aggregation inhibitory action may be able to improve this decrease in the number of neurons. Therefore, brain slices were prepared from mice treated with isoprenaline, and the number of neurons was counted. As a measurement method, a 0.1 mm2 box as shown in Fig. 8 (a) is drawn on the entorhinal cortex or temporal area, and the number of cells in the box is counted and averaged. The result was taken as the value of 1 slice. Two slices were prepared from one individual. As a result, as shown in Fig. 8 (b) and Fig.
- isoprenaline suppressed the decrease in the number of cells in the entoehinal cortex and temporal area exhibited by P301L tau Tg mice. did. Therefore, it was suggested that isoprenaline may improve the decrease in the number of neurons by suppressing tau aggregation.
- Mice is the number of mice used
- Slice is the number of slices per individual for which the number of cells was measured.
- Example 8 The change of tau phosphorylation in TBS soluble fraction collected from WT tau Tg mice was examined. As a result, as shown in FIG. 9, isoprenaline increased the dephosphorylation of tau recognized by the monoclonal antibody tau1.
- FIG. 9A shows the TBS soluble fraction
- FIG. 9B shows the ratio of dephosphorylated tau to tau. Therefore, it was suggested that isoprenaline suppresses tau aggregation and tau phosphorylation in mice.
- Example 2 shows the effect by isoprenaline
- the catecholamine structure skeleton has been found as a novel common skeleton that suppresses tau aggregation (Example 2 above)
- Example 9 Tau (10 ⁇ M), d- and d / l-isoprenalin (1-100 ⁇ M) and thioflavin T were mixed. Heparin was then added and incubated at 37 ° C. to aggregate tau. In addition, at the time indicated in the figure, the thioflavin T activity in the incubation sample was measured, and the tau aggregation inhibitory action by the compound was examined.
- FIG. 10 (a) is a diagram in which the effect of d-isoprenaline on the activity of thioflavin T is examined. As shown in FIGS. 10 (a) and 10 (b), d-isoprenalin exhibited almost the same thioflavin T activity inhibitory action as d / l-isoprenalin.
- FIG. 11 shows the results of SDS-PAGE Western blotting showing the effect of suppressing tau aggregation detected by sucrose density gradient centrifugation, in which d-isoprenalin is shown in FIG. 11 (a) and FIG. 11 (b) is shown. Results for d / l-isoprenalin are shown.
- d-isoprenalin clearly reduces tau (granular tau aggregates and tau fibers) detected after Fr3 in substantially the same manner as d / l-isoprenalin. It was.
- FIG. 12 is a diagram showing the morphological change of tau aggregation using an atomic force microscope, in which FIG. 12 (a) is a photograph of a control, and FIG. 12 (b) is a d ⁇ for a tau aggregation sample.
- P301L tau Tg mice were used. 20- to 21-month-old P301L tau Tg mice were ingested with d-isoprenalin (2.168 mg / g fed) mixed for 3 months. Thereafter, cerebral cortex and hippocampus were collected from the mice and stored at ⁇ 80 ° C. Thereafter, TBS soluble fraction and sarkosyl insoluble fraction were prepared from these brain tissues, and tau was detected by SDS-PAGE Western blotting.
- FIG. 13 is a diagram showing a decrease in sarkosyl-insoluble tau by d-isoprenalin in the cerebral cortex of P301L tau Tg mice, of which FIG. 13 (a) shows the tau of the sarkosyl-insoluble fraction, and FIG. 13 (b) shows the TBS-soluble fraction. In which Tau and endogenous control GAPDH were detected.
- FIG. 14 is a graph showing a decrease in sarkosyl-insoluble tau by d-isoprenalin in the cerebral cortex of P301L tau Tg mice, and FIG. 14 (a) shows the ratio of sarkosyl-insoluble tau to TBS-soluble tau as shown in FIG. b) shows the ratio of tau to GAPDH in the TBS soluble fraction.
- d-isoprenalin clearly reduced the amount of insoluble tau in the cerebral cortex of P301L tau Tg mice.
- FIG. 15 is a graph showing a decrease in sarkosyl-insoluble tau by d-isoprenalin in the hippocampus of P301L tau Tg mice, of which FIG. 15 (a) shows the tau of the sarkosyl-insoluble fraction and FIG. 15 (b) shows the TBS-soluble fraction. Tau and endogenous control GAPDH were detected.
- FIG. 15 (a) shows the tau of the sarkosyl-insoluble fraction
- FIG. 15 (b) shows the TBS-soluble fraction. Tau and endogenous control GAPDH were detected.
- FIG. 16 is a graph showing a decrease in sarkosyl-insoluble tau by d-isoprenalin in the hippocampus of P301L tau Tg mice.
- FIG. 16 (a) shows the ratio of sarkosyl-insoluble tau to TBS-soluble tau in FIG. b) shows the ratio of tau to GAPDH in the TBS soluble fraction.
- d-isoprenalin clearly reduced the amount of insoluble tau in the hippocampus of P301L tau Tg mice.
Abstract
Description
タウと結合できる化合物を検索した。10μMの2N4Rタウ(タウ-441 ヒューマン)と10μMのヘパリンとを混合し、37℃でインキュベートし、タウを凝集させた。この凝集したタウサンプル(1ml)をショ糖密度勾配溶液(20%, 30%, 40%, 50%を1mlずつ重層)にロードし、遠心した(200000xg, 2h, 20℃)。その後、上層から1mlずつ溶液を回収し、フラクション(Fr)1-5のサンプルとした。また、ペレットはHEPES溶液に懸濁し、Fr6とした。その後、Fr1,3,5に含まれるタウと所定の6600の化合物との結合能を表面プラズモン共鳴法で解析した。表面プラズモン共鳴法とは、薄金膜上に固定した分子の重さの変化等によって生じる屈折率の変化をモニターすることにより、2種類の物質の分子間相互作用を解析する手法である。表面プラズモン共鳴法は、市販の表面プラズモン共鳴装置、例えばBIAcore2000 (Pharmacia Biosensor社製)によって行うことが可能である。その結果、6600の化合物のうち、111個の化合物がタウと結合することを見出した。
次に、(R)-(-)-エピネフリン及びピロカテコールバイオレットの類似構造体が、タウ凝集を抑制するかどうかをチオフラビンT染色法により解析した。その結果、図1に示されるように、レボドパ、ドーパミン、ノルエピネフリン、及びイソプレナリンは、(R)-(-)-エピネフリンと同様に、チオフラビンT活性を顕著に減少させた。ここで、図1(a)は(R)-(-)-エピネフリン、図1(b)はレボドパ、図1(c)はドーパミン、図1(d)はノルエピネフリン、図1(e)はイソプレナリンによるチオフラビンT活性の変化を示している。
次に、イソプレナリンが培養細胞において、タウ凝集を抑制するかどうかを検討した。細胞はヒトのP301L変異体タウ(タウアイソフォームの301番目のプロリンがロイシンに変異したタウ)をステーブルに発現したNeuro2a cell lineを使用した。これらの細胞にイソプレナリンを0.01、0.1及び1μMの濃度で48時間処置した。その後、SDS-不溶性フラクションを採取し、タウの量の変化を検討した。その結果、図3に示されるように、イソプレナリンは、ポジティブコントロールのGSK3β(グリコーゲン合成酵素キナーゼ3β)阻害剤(GSK3βの機能を物理的又は化学的に阻害する物質を意味する)である塩化リチウムと同様にSDS不溶性タウの量を減少させた。ここで、図3(a)はSDS不溶性フラクションのタウを検出したものであり、図3(b)は図3(a)をグラフ化したものでイソプレナリンはSDS不溶性タウの量を減少させることを示している。
AT8のタウリン酸化はAD病態で観察されるタウの構造変化(MC1抗体で検出可)を誘発することが知られている。そこで、COS-7細胞(アフリカミドリザル腎由来)にWT tauを発現させ、MC1抗体を用いたドットブロット法でタウの構造変化を検出した。ドットブロット法は、タンパク質を電気泳動により分離することなくニトロセルロース膜やPVDF膜に固定し、酵素標識抗体でタンパク質量を特異的に定量する方法である。その結果、図5(a)(b)に示されるように、イソプレナリンはMC1抗体で検出されるタウの構造変化を減少させた。ここで、図5(a)はTBS可溶性フラクションでのMC1抗体陽性タウ、タウリン酸化(AT8サイト)、タウ及びGAPDH(内在性コントロール)を検出したもので、図5(b)はタウに対するMC1抗体陽性タウの比率を示す。また、図5(c)に示されるように、同様の条件において、イソプレナリンはリン酸化も減少させた。ここで、図5(c)はタウに対するリン酸化タウの比率を示す。
イソプレナリンが微小管とタウとの結合にどのような影響を及ぼすかを検討した。WT tauを発現したCOS-7細胞にイソプレナリン10μMを24時間処置後、RA buffer(0.1μM MES, 0.5mM MgSO4, 1mM EGTA, 2mM DTT, 0.1% TritonX-100, 20μM taxol, 2mM GTP)でホモジナイズした。3000xgにて25℃で5分間遠心分離後、トータルフラクションとして上清を採取した。このトータルフラクションを更に100000xgにて20℃で20分間遠心分離し、ペレット(微小管フラクション)を採取した。このようにしてWT tauを発現したCOS-7細胞から微小管フラクションを採取し、タウと微小管安定化の指標であるアセチル化チューブリンを検出した。
次に、イソプレナリンがマウスにおいて、タウ凝集を抑制するかどうかを検討した。P301L tau Tgマウスに粉餌に混合したイソプレナリン(1.5mg/g fed)を3か月間摂取させた。その後、マウスから大脳皮質及び海馬を採取し、-80℃に保存した。これら動物組織から可溶性タウ及び不溶性タウを含む画分を得るため、まず、凍結組織にTBS溶液を加え、ホモジナイズした後に遠心し(23000rpm, 15min, 4℃)、上清とペレットに分けた。その内、上清をTBS可溶性フラクション(可溶性タウを含む)とした。また、ペレットに0.32M スクロースを加え、再度ホモジナイズした後に遠心し(23000rpm, 15min, 4℃)、上清(タウ凝集体を含む)とペレット(核を含む)に分けた。その後、上清に界面活性化剤(1%サルコシル)を加え、インキュベーションし(37℃, 1h)、遠心した(200000xg , 1h, 4℃)。ペレットをレムリバッファー(2-メルカプトエタノール入り)で溶解したものをサルコシル不溶性フラクションとした。TBS可溶性フラクション及びサルコシル不溶性フラクションにおけるタウをSDS-PAGEウェスタンブロット法で検出した。その結果、図7に示されるように、イソプレナリンはP301L tau Tgマウスの脳内におけるサルコシル不溶性タウの量を減少させた。ここで、図7(a)はサルコシル不溶性フラクションのタウを検出したもので、図7(b)は図7(a)を定量・グラフ化したものである。NtgはNon-transgenic mouseを意味する。
P301L tau Tgマウスの脳内では、タウ凝集の進展に伴って、神経細胞数が低下する。このため、タウ凝集抑制作用を有するイソプレナリンはこの神経細胞数の低下を改善できる可能性がある。そこで、イソプレナリンを処置したマウスから脳スライスを作製し、神経細胞数をカウントした。その測定方法として、図8(a)に示されるような0.1ミリ平方メートルのボックスを嗅内皮質(entorhinal cortex)または側頭領域(temporal area)に描き、その中の細胞数をカウントし、平均化したものを1スライスの値とした。スライスは1個体から2枚作製し、その結果、図8(b)及び図8(c)に示されるように、イソプレナリンはP301L tau Tgマウスが示すentoehinal cortex及びtemporal areaにおける細胞数の低下を抑制した。従って、イソプレナリンはタウ凝集を抑制することで、神経細胞数の低下を改善できる可能性が示唆された。なお、図8(b)及び図8(c)において、Miceは使用したマウス数であり、Sliceは細胞数を測定した1個体あたりのスライスの数である。
WT tau Tgマウスから採取したTBS可溶性フラクションにおけるタウリン酸化の変化を検討した。その結果、図9に示されるように、イソプレナリンはモノクローナル抗体tau1で認識するタウの脱リン酸化を増加させた。ここで、図9(a)はTBS可溶性フラクションであり、図9(b)はタウに対する脱リン酸化タウの比率である。このため、マウスにおいてもイソプレナリンはタウ凝集及びタウのリン酸化を抑制することが示唆された。
タウ(10μM)、d-及びd/l-イソプレナリン(1~100μM)とチオフラビンTを混合した。その後、ヘパリンを加え、37℃でインキュベーションし、タウを凝集させた。また、図中に示した時間において、インキュベーションサンプル中のチオフラビンT活性を測定し、化合物によるタウ凝集抑制作用を検討した。図10(a)はd-イソプレナリン、図10(b)はd/l-イソプレナリンがチオフラビンT活性に及ぼす影響を検討した図である。図10(a)(b)に示されるように、d-イソプレナリンは、d/l-イソプレナリンとほぼ同様のチオフラビンT活性抑制作用を示した。
Claims (6)
- イソプレナリン又はその塩を含む、タウオパチーの予防及び/又は治療に用いられるタウ凝集阻害剤。
- 前記イソプレナリンはd体である請求項1記載のタウ凝集阻害剤。
- 前記イソプレナリンはd/l体である請求項1記載のタウ凝集阻害剤。
- 前記タウオパチーは、AD、ダウン症、Pick病、皮質基底核変性症(CBD)、又は進行性核上性麻痺(PSP)である請求項1記載のタウ凝集阻害剤。
- 更に製薬上許容される等張化剤、緩衝剤、溶解補助剤、防腐剤、及びpH調整剤から選択される1又はそれ以上の添加剤を含有する請求項1記載のタウ凝集阻害剤。
- ドーパミン、ドブタミン、レボドパ、レボドパ/カルビドパ、トリメトキノール、ヘキソプレナリン、メチルドパ及びドロキシドパからなる群から選ばれたカテコール構造含有化合物又はその塩を含む、タウオパチーの予防及び/又は治療に用いられるタウ凝集阻害剤。
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/349,160 US20140249180A1 (en) | 2011-10-03 | 2012-10-03 | Tau aggregation inhibitor |
EP12837822.1A EP2764863B1 (en) | 2011-10-03 | 2012-10-03 | Tau aggregation inhibitor |
JP2013537416A JP6126531B2 (ja) | 2011-10-03 | 2012-10-03 | タウ凝集阻害剤 |
US15/894,414 US20180161288A1 (en) | 2011-10-03 | 2018-02-12 | Tau aggregation inhibitor |
US17/464,440 US20210393551A1 (en) | 2011-10-03 | 2021-09-01 | Tau aggregation inhibitor |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2011219059 | 2011-10-03 | ||
JP2011-219059 | 2011-10-03 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/349,160 A-371-Of-International US20140249180A1 (en) | 2011-10-03 | 2012-10-03 | Tau aggregation inhibitor |
US15/894,414 Division US20180161288A1 (en) | 2011-10-03 | 2018-02-12 | Tau aggregation inhibitor |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2013051266A1 true WO2013051266A1 (ja) | 2013-04-11 |
Family
ID=48043446
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2012/006363 WO2013051266A1 (ja) | 2011-10-03 | 2012-10-03 | タウ凝集阻害剤 |
Country Status (4)
Country | Link |
---|---|
US (3) | US20140249180A1 (ja) |
EP (1) | EP2764863B1 (ja) |
JP (2) | JP6126531B2 (ja) |
WO (1) | WO2013051266A1 (ja) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014162737A1 (ja) * | 2013-04-02 | 2014-10-09 | 学校法人同志社 | タウ凝集阻害剤 |
JP2020523556A (ja) * | 2017-05-16 | 2020-08-06 | アンプリオン、インコーポレイテッド | ミスフォールドタウタンパク質の検出 |
JP2021523126A (ja) * | 2018-05-03 | 2021-09-02 | ハフ イアー インスティテュート | 蓄積した病理学的Tauタンパク質を低減する方法 |
US11224667B2 (en) | 2016-07-06 | 2022-01-18 | National Center For Geriatrics And Gerontology | 11C-labeled catechol derivative, pet probe of phosphorylated tau aggregation inhibitor using the same, and production method of the same |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003530432A (ja) * | 2000-04-12 | 2003-10-14 | ミナーヴァ・バイオテクノロジーズ・コーポレーション | 神経変性疾患の治療 |
JP2003532634A (ja) * | 1999-12-30 | 2003-11-05 | プロテオテック・インコーポレイテッド | アミロイド症およびα−シヌクレイン線維疾患の処置用ポリヒドロキシル化芳香族化合物 |
JP2004534854A (ja) | 2001-07-16 | 2004-11-18 | ザ・ユニバーシティ・コート・オブ・ザ・ユニバーシティ・オブ・アバディーン | アルツハイマーおよび関連する神経変性障害の処置のためのタウ凝集阻害剤としてのナフトキノン誘導体 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1144905A (en) * | 1965-03-25 | 1969-03-12 | Fisons Pharmaceuticals Ltd | Substituted bis-(2-carboxy-chromonyl-oxy) derivatives and preparation and pharmaceutical compositions thereof |
US3885047A (en) * | 1972-06-16 | 1975-05-20 | Mead Johnson & Co | Ocular hypotensive process employing dextrorotatory phenethanolamines |
JPS62106015A (ja) * | 1985-10-31 | 1987-05-16 | Sumitomo Pharmaceut Co Ltd | 抗痴呆薬 |
WO2002053104A2 (en) * | 2001-01-02 | 2002-07-11 | Sention, Inc. | Use of catecholamine reuptake inhibitors to enhance memory |
JP2005505548A (ja) * | 2001-08-29 | 2005-02-24 | ユクロ ヨーロピアン コントラクト リサーチ ゲーエムベーハー ウント コー.カーゲー | 神経細胞変性の病気の治療のためのβ−アドレナリン受容体拮抗薬を使用する方法 |
PL369311A1 (en) * | 2001-12-11 | 2005-04-18 | Eli Lilly And Company | Use of norepinephrine reuptake inhibitors for the treatment of cognitive failure |
US20050215562A1 (en) * | 2003-06-23 | 2005-09-29 | Patrick Tremblay | Methods for treating protein aggregation disorders |
US8669048B2 (en) * | 2008-06-24 | 2014-03-11 | Parkinson's Institute | Pluripotent cell lines and methods of use thereof |
WO2011071920A2 (en) * | 2009-12-07 | 2011-06-16 | Board Of Regents, The University Of Texas System | Promoting cycling of apoe4 isoform |
US9072746B2 (en) * | 2010-04-22 | 2015-07-07 | The Board Of Trustees Of The Leland Stanford Junior University | Method for enhancing learning and memory impaired by neurodegenerative disorders and compounds and compositions for effecting the same |
KR20130059361A (ko) * | 2011-07-06 | 2013-06-05 | 미츠비시 쥬고교 가부시키가이샤 | 발전기를 구비한 에너지 추출 장치 및 발전기를 구비한 에너지 추출 장치의 운전방법 |
EP2962687B1 (en) * | 2013-04-02 | 2019-06-05 | The Doshisha | Tau aggregation inhibitor |
-
2012
- 2012-10-03 EP EP12837822.1A patent/EP2764863B1/en active Active
- 2012-10-03 WO PCT/JP2012/006363 patent/WO2013051266A1/ja active Application Filing
- 2012-10-03 US US14/349,160 patent/US20140249180A1/en not_active Abandoned
- 2012-10-03 JP JP2013537416A patent/JP6126531B2/ja not_active Expired - Fee Related
-
2017
- 2017-04-06 JP JP2017075939A patent/JP6353110B2/ja not_active Expired - Fee Related
-
2018
- 2018-02-12 US US15/894,414 patent/US20180161288A1/en not_active Abandoned
-
2021
- 2021-09-01 US US17/464,440 patent/US20210393551A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003532634A (ja) * | 1999-12-30 | 2003-11-05 | プロテオテック・インコーポレイテッド | アミロイド症およびα−シヌクレイン線維疾患の処置用ポリヒドロキシル化芳香族化合物 |
JP2003530432A (ja) * | 2000-04-12 | 2003-10-14 | ミナーヴァ・バイオテクノロジーズ・コーポレーション | 神経変性疾患の治療 |
JP2004534854A (ja) | 2001-07-16 | 2004-11-18 | ザ・ユニバーシティ・コート・オブ・ザ・ユニバーシティ・オブ・アバディーン | アルツハイマーおよび関連する神経変性障害の処置のためのタウ凝集阻害剤としてのナフトキノン誘導体 |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014162737A1 (ja) * | 2013-04-02 | 2014-10-09 | 学校法人同志社 | タウ凝集阻害剤 |
US9907799B2 (en) | 2013-04-02 | 2018-03-06 | The Doshisha | Tau aggregation inhibitor |
US11224667B2 (en) | 2016-07-06 | 2022-01-18 | National Center For Geriatrics And Gerontology | 11C-labeled catechol derivative, pet probe of phosphorylated tau aggregation inhibitor using the same, and production method of the same |
JP2020523556A (ja) * | 2017-05-16 | 2020-08-06 | アンプリオン、インコーポレイテッド | ミスフォールドタウタンパク質の検出 |
JP7308154B2 (ja) | 2017-05-16 | 2023-07-13 | アンプリオン、インコーポレイテッド | ミスフォールドタウタンパク質の検出 |
JP2021523126A (ja) * | 2018-05-03 | 2021-09-02 | ハフ イアー インスティテュート | 蓄積した病理学的Tauタンパク質を低減する方法 |
Also Published As
Publication number | Publication date |
---|---|
EP2764863A1 (en) | 2014-08-13 |
JPWO2013051266A1 (ja) | 2015-03-30 |
JP6126531B2 (ja) | 2017-05-10 |
US20210393551A1 (en) | 2021-12-23 |
EP2764863B1 (en) | 2020-03-11 |
JP2017119722A (ja) | 2017-07-06 |
EP2764863A4 (en) | 2015-11-18 |
US20140249180A1 (en) | 2014-09-04 |
JP6353110B2 (ja) | 2018-07-04 |
US20180161288A1 (en) | 2018-06-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Gao et al. | Tau in Alzheimer's disease: mechanisms and therapeutic strategies | |
US20220249515A1 (en) | Ganaxolone for use in treating genetic epileptic disorders | |
US20210393551A1 (en) | Tau aggregation inhibitor | |
US20200338040A1 (en) | Methods for treating alzheimer's disease and related disorders | |
JP6250394B2 (ja) | 軽度の認知障害(mci)および関連障害の処置方法 | |
JP2009149524A (ja) | アルツハイマー病の予防・治療剤 | |
US20210093610A1 (en) | (3ar)-1,3a,8-trimethyl-1 ,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indol-5-yl phenylcarbamate and methods of treating or preventing neurodegeneration | |
US20210038589A1 (en) | Uses, compositions and methods | |
JP2023118923A (ja) | アルファ-シヌクレインの調節因子 | |
US9072730B2 (en) | Method of improving cognitive functions in individuals with down syndrome and/or alzheimer's disease | |
FR2905009A1 (fr) | Methode de criblage de composes aux proprietes anti-amyloide | |
US20210338647A1 (en) | Combination of Acetylcholinesterase Inhibitor and 5-HT4 Receptor Agonist As Neuroprotective Agent In the Treatment of Neurodegenerative Diseases | |
AU2022291519A1 (en) | Small Molecule Drugs And Related Methods For Treatment Of Diseases Related To Aß42 Oligomer Formation | |
TW201609640A (zh) | 吲哚基及吲哚啉基異羥肟酸於治療神經退化病症或認知缺乏之用途 | |
CN111601643A (zh) | 用于改善溶酶体功能和治疗神经退行性疾病的方法和组合物 | |
RU2797677C2 (ru) | Модуляторы альфа-синуклеина | |
WO2024064897A1 (en) | Methods of reducing neurodegeneration associated with neurodegenerative diseases | |
WO2023230560A1 (en) | Treatment of organic acidemias or pantothenate kinase associated neurodegeneration with modulators of pantothenate kinases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 12837822 Country of ref document: EP Kind code of ref document: A1 |
|
DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 14349160 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 2013537416 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012837822 Country of ref document: EP |